Management of Pancreatic Enzyme Supplements in Chronic Liver Disease

Patient Assessment and Monitoring

Patients with chronic liver disease should receive consultation with a pharmacist experienced in hepatobiliary disease to identify high-risk medications, polypharmacy, and therapy modifications every 6 months, as recommended by the American Association for the Study of Liver Diseases 1
The European Association for the Study of the Liver suggests that patients with advanced liver disease should undergo liver-specific physical examination and measurement of liver function tests at least every 6 months to detect progression of liver disease 1

The American Gastroenterological Association recommends that patients with cirrhosis have adequate protein and calorie intake (1.2-1.5 g/kg/day protein and 35-40 kcal/kg ideal body weight) 2
The European Association for the Study of the Liver notes that malabsorption can occur in advanced liver disease, potentially warranting digestive enzyme support 3

The American Association for the Study of Liver Diseases advises against using supplements containing manganese in cirrhosis patients, as they have elevated total body manganese levels that may accumulate in the basal ganglia 4
The American Association for the Study of Liver Diseases recommends reviewing all concurrent medications for potential interactions, particularly those metabolized by cytochrome P450 enzymes 5
The American Association for the Study of Liver Diseases suggests that patients with decompensated cirrhosis require heightened caution, closer monitoring, and pharmacist involvement when using pancreatic enzyme supplements 1

Supplement fat-soluble vitamins (A, D, E, K) when deficiencies are documented, particularly in cholestatic liver diseases where fat malabsorption is prominent 6

Patients with advanced liver disease should undergo assessment for fat-soluble vitamin deficiencies (A, D, E, K), which may indicate true malabsorption requiring intervention 6